801 related articles for article (PubMed ID: 29258105)
1. Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases.
Izumoto H; Hiraoka A; Ishimaru Y; Murakami T; Kitahata S; Ueki H; Aibiki T; Okudaira T; Miyamoto Y; Yamago H; Iwasaki R; Tomida H; Mori K; Kishida M; Tsubouchi E; Miyata H; Ninomiya T; Kawasaki H; Hirooka M; Matsuura B; Abe M; Hiasa Y; Michitaka K; Kudo M
Oncology; 2017; 93 Suppl 1():120-126. PubMed ID: 29258105
[TBL] [Abstract][Full Text] [Related]
2. Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.
Arizumi T; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Ueshima K; Kamata K; Minaga K; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
Dig Dis; 2017; 35(6):589-597. PubMed ID: 29040992
[TBL] [Abstract][Full Text] [Related]
3. The Overall Survival of Patients with Hepatocellular Carcinoma Correlates with the Newly Defined Time to Progression after Transarterial Chemoembolization.
Arizumi T; Ueshima K; Iwanishi M; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
Liver Cancer; 2017 Jun; 6(3):227-235. PubMed ID: 28626733
[TBL] [Abstract][Full Text] [Related]
4. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
[TBL] [Abstract][Full Text] [Related]
5. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
[TBL] [Abstract][Full Text] [Related]
6. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
7. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
8. Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
Hiraoka A; Kumada T; Kudo M; Hirooka M; Koizumi Y; Hiasa Y; Tajiri K; Toyoda H; Tada T; Ochi H; Joko K; Shimada N; Deguchi A; Ishikawa T; Imai M; Tsuji K; Michitaka K;
Dig Dis; 2017; 35(6):602-610. PubMed ID: 29040999
[TBL] [Abstract][Full Text] [Related]
9. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
10. A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.
Ni JY; Fang ZT; Sun HL; An C; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH
Eur Radiol; 2020 Apr; 30(4):2377-2390. PubMed ID: 31900694
[TBL] [Abstract][Full Text] [Related]
11. Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma.
Kim JY; Sinn DH; Gwak GY; Choi GS; Saleh AM; Joh JW; Cho SK; Shin SW; Carriere KC; Ahn JH; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Clin Mol Hepatol; 2016 Jun; 22(2):250-8. PubMed ID: 27377909
[TBL] [Abstract][Full Text] [Related]
12. New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization.
Kim JH; Shim JH; Lee HC; Sung KB; Ko HK; Ko GY; Gwon DI; Kim JW; Lim YS; Park SH
Liver Int; 2017 Dec; 37(12):1861-1868. PubMed ID: 28581250
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization.
Ciria R; López-Cillero P; Gallardo AB; Cabrera J; Pleguezuelo M; Ayllón MD; Luque A; Zurera L; Espejo JJ; Rodríguez-Perálvarez M; Montero JL; de la Mata M; Briceño J
Eur J Surg Oncol; 2015 Sep; 41(9):1153-61. PubMed ID: 26118317
[TBL] [Abstract][Full Text] [Related]
14. Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2.
Arizumi T; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Ueshima K; Kamata K; Minaga K; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
Dig Dis; 2017; 35(6):583-588. PubMed ID: 29040991
[TBL] [Abstract][Full Text] [Related]
15. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.
Chen R; Gan Y; Ge N; Chen Y; Wang Y; Zhang B; Wang Y; Ye S; Ren Z
J Vasc Interv Radiol; 2016 Dec; 27(12):1829-1836. PubMed ID: 27553917
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effects of transarterial chemoembolization for advanced hepatocellular carcinoma between patients with and without extrahepatic metastases.
Yoo JJ; Lee JH; Lee SH; Lee M; Lee DH; Cho Y; Lee YB; Yu SJ; Kim HC; Kim YJ; Yoon JH; Kim CY; Lee HS
PLoS One; 2014; 9(11):e113926. PubMed ID: 25427152
[TBL] [Abstract][Full Text] [Related]
18. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.
Heng-jun G; Yao-jun Z; Min-shan C; Mei-xian C; Jun-ting H; Li X; Lau WY
Liver Int; 2014 Apr; 34(4):612-20. PubMed ID: 24028297
[TBL] [Abstract][Full Text] [Related]
19. Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma.
Yang B; Zheng B; Yang M; Zeng Z; Yang F; Pu J; Li C; Liao Z
Hepatol Int; 2018 Sep; 12(5):417-428. PubMed ID: 30073454
[TBL] [Abstract][Full Text] [Related]
20. Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma.
Hickey R; Mouli S; Kulik L; Desai K; Thornburg B; Ganger D; Baker T; Abecassis M; Ralph Kallini J; Gabr A; Gates VL; Benson Iii AB; Lewandowski RJ; Salem R
J Vasc Interv Radiol; 2016 Jun; 27(6):795-802. PubMed ID: 27038686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
